Close

Baird Maintains an 'Outperform' on BioMarin Pharmaceutical (BMRN); Valuation Still Attractive, Remains a Core Holding Sep 23, 2011 07:47AM
Notable Analyst Rating Changes 02/18: (TRGL) (SPWRA) (BRCD) (ZMH) Upgraded; (ACOR) (VCLK) (BMRN) (PEP) Downgraded Feb 18, 2011 11:20AM
Notable Analyst Rating Changes of the Day 02/08: HD, AMZN, ARAY, WGO Upgraded; BMRN, ARG, HK Downgraded Feb 8, 2010 10:45AM
Baird Reiterates an Outperform Rating on BioMarin Pharmaceutical (BMRN); Raise PT Feb 1, 2010 10:38AM
Baird Is a Buyer of BioMarin (BMRN) On Genzyme-Related Weakness Jun 16, 2009 09:55AM


May 7, 2009 10:29AM Notable Analyst Rating Changes 5/7: BAC, COF, FITB, RTP Upgraded; T, CMA, STI, TSO Downgraded
Mar 19, 2009 07:51AM Baird Said a Genzyme (GENZ) Takeover Of BioMarin (BMRN) Makes Sense To Them
Jul 2, 2008 09:50AM Notable Analyst Rating Changes 7/2: XOM, VSE, RAI, FITB Upgraded; DEO, PXP, UAUA Downgraded
Feb 13, 2008 09:01AM Baird Reiterates Outperform on BioMarin Pharma (BMRN); Ups PT to $46
Jan 30, 2008 12:29PM Baird Reiterates Outperform on BioMarin Pharmaceutical (BMRN)